Chicago Equity Partners LLC Acquires Shares of 2,280 Alexion Pharmaceuticals, Inc. (ALXN)

Chicago Equity Partners LLC acquired a new stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,280 shares of the biopharmaceutical company’s stock, valued at approximately $320,000.

Several other institutional investors have also made changes to their positions in ALXN. Dimensional Fund Advisors LP lifted its position in shares of Alexion Pharmaceuticals by 4.4% in the first quarter. Dimensional Fund Advisors LP now owns 321,459 shares of the biopharmaceutical company’s stock valued at $38,975,000 after acquiring an additional 13,679 shares in the last quarter. Oregon Public Employees Retirement Fund lifted its position in shares of Alexion Pharmaceuticals by 0.9% in the second quarter. Oregon Public Employees Retirement Fund now owns 23,624 shares of the biopharmaceutical company’s stock valued at $2,874,000 after acquiring an additional 200 shares in the last quarter. LS Investment Advisors LLC lifted its position in shares of Alexion Pharmaceuticals by 6.6% in the second quarter. LS Investment Advisors LLC now owns 6,533 shares of the biopharmaceutical company’s stock valued at $795,000 after acquiring an additional 402 shares in the last quarter. Peregrine Capital Management LLC lifted its position in shares of Alexion Pharmaceuticals by 24.9% in the second quarter. Peregrine Capital Management LLC now owns 97,420 shares of the biopharmaceutical company’s stock valued at $11,853,000 after acquiring an additional 19,427 shares in the last quarter. Finally, Gradient Investments LLC lifted its position in shares of Alexion Pharmaceuticals by 8.0% in the second quarter. Gradient Investments LLC now owns 2,555 shares of the biopharmaceutical company’s stock worth $311,000 after buying an additional 189 shares in the last quarter. Institutional investors and hedge funds own 96.71% of the company’s stock.

In other news, EVP Julie O’neill sold 4,375 shares of the firm’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $145.44, for a total transaction of $636,300.00. Following the sale, the executive vice president now directly owns 26,092 shares in the company, valued at approximately $3,794,820.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ann M. Veneman sold 835 shares of the firm’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $145.81, for a total value of $121,751.35. Following the sale, the director now owns 5,480 shares in the company, valued at $799,038.80. The disclosure for this sale can be found here. Insiders have sold a total of 16,490 shares of company stock worth $2,337,251 over the last ninety days. 4.35% of the stock is owned by insiders.

A number of research firms recently commented on ALXN. TheStreet downgraded Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Friday, November 10th. Zacks Investment Research downgraded Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, November 1st. Royal Bank Of Canada boosted their target price on Alexion Pharmaceuticals to $166.00 in a research report on Tuesday, October 24th. Stifel Nicolaus decreased their price objective on Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating on the stock in a research report on Tuesday, October 24th. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $170.00 price objective on shares of Alexion Pharmaceuticals in a research report on Monday, October 23rd. Six research analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have issued a strong buy rating to the stock. Alexion Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $154.01.

ILLEGAL ACTIVITY NOTICE: “Chicago Equity Partners LLC Acquires Shares of 2,280 Alexion Pharmaceuticals, Inc. (ALXN)” was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://ledgergazette.com/2017/11/19/chicago-equity-partners-llc-acquires-shares-of-2280-alexion-pharmaceuticals-inc-alxn.html.

Alexion Pharmaceuticals, Inc. (ALXN) opened at $110.87 on Friday. The stock has a market capitalization of $24,769.47, a price-to-earnings ratio of 22.67, a P/E/G ratio of 1.21 and a beta of 1.22. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.96 and a quick ratio of 2.51. Alexion Pharmaceuticals, Inc. has a 52 week low of $96.18 and a 52 week high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, topping the consensus estimate of $1.32 by $0.12. The company had revenue of $859.00 million for the quarter, compared to the consensus estimate of $864.34 million. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The firm’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same period last year, the firm earned $1.23 EPS. analysts forecast that Alexion Pharmaceuticals, Inc. will post 4.81 earnings per share for the current fiscal year.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply